接受 CARv3-TEAM-E T 细胞治疗的受试者的长期随访
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
研究概览
地位
详细说明
This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.
No investigational treatment will be administered in this study.
The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.
Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).
Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Matthew J Frigault, MD
- 电话号码:617-643-6175
- 邮箱:mfrigault@mgb.org
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Massachusetts General Hospital
-
首席研究员:
- Matthew J Frigault, MD
-
接触:
- Matthew J Frigault, MD
- 电话号码:(617) 724-4000
- 邮箱:mfrigault@mgb.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit
描述
Inclusion Criteria:
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
Exclusion Criteria:
Subjects meeting the following criterion are to be excluded from study participation:
- Subject unable to comply with study requirements
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
CAR T cells
|
CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol Tumor Biopsy per protocol Blood Test per protocol |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival
大体时间:1 month
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
1 month
|
|
Overall Survival
大体时间:6 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
6 months
|
|
Overall Survival
大体时间:12 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
12 months
|
|
Overall Survival
大体时间:24 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
24 months
|
|
Progresison Free Survival
大体时间:1 month
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
1 month
|
|
Progresison Free Survival
大体时间:6 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
6 months
|
|
Progresison Free Survival
大体时间:12 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
12 months
|
|
Progresison Free Survival
大体时间:24 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
24 months
|
|
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
大体时间:Up to 15 Years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
Up to 15 Years
|
|
New incidence of a hematologic disorder
大体时间:up to 15 years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
up to 15 years
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
大体时间:up to 15 years
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) |
up to 15 years
|
|
Vector-derived RCL
大体时间:baseline and in 3 months, 6 months, and annually up to 15 years
|
Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA). |
baseline and in 3 months, 6 months, and annually up to 15 years
|
|
Assessment of CAR T cells persistence by VCN in peripheral blood
大体时间:baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence |
baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
|
Progression-free Survival
大体时间:From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
|
Overall Survival
大体时间:From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
The time from post-CAR T cells infusion to the date of death. |
From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
合作者和调查者
调查人员
- 首席研究员:Matthew J Frigault, MD、Massachusetts General Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 20-721
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 共享时间框架
Data can be shared no earlier than 1 year following the date of publication
IPD 共享访问标准
Contact the Partners Innovations team at http://www.partners.org/innovation
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.